Phathom Pharmaceuticals, Inc. financial data

Symbol
PHAT on Nasdaq
Industry
Pharmaceutical Preparations
Location
100 Campus Drive,, Suite 102, Florham Park, NJ
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 571 % -44.8%
Quick Ratio 4.12 %
Debt-to-equity -275 % +63.3%
Return On Equity 162 % -67.1%
Return On Assets -92.8 % -22%
Operating Margin -502 % +98%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 69.6M shares +19.1%
Common Stock, Shares, Outstanding 58M shares 0%
Entity Public Float 470M USD +138%
Common Stock, Value, Issued 6K USD +20%
Weighted Average Number of Shares Outstanding, Basic 63.2M shares +23.2%
Weighted Average Number of Shares Outstanding, Diluted 63.2M shares +23.2%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 55.3M USD +8001%
Cost of Revenue 7.97M USD +4674%
Research and Development Expense 34.1M USD -31.7%
General and Administrative Expense 91.6M USD +2.05%
Operating Income (Loss) -277M USD -65.8%
Nonoperating Income (Expense) -56.9M USD -65.9%
Net Income (Loss) Attributable to Parent -334M USD -65.8%
Earnings Per Share, Basic -5.29 USD/shares -34.6%
Earnings Per Share, Diluted -5.29 USD/shares -34.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 297M USD -22.1%
Inventory, Net 3.21M USD +166%
Assets, Current 360M USD -9.39%
Property, Plant and Equipment, Net 1.48M USD -31.2%
Operating Lease, Right-of-Use Asset 613K USD -58.4%
Other Assets, Noncurrent 1.69M USD +0.06%
Assets 378M USD -8.58%
Accounts Payable, Current 10.5M USD -16.6%
Accrued Liabilities, Current 53.2M USD +210%
Contract with Customer, Liability, Current 19.8M USD +178%
Liabilities, Current 85.7M USD +121%
Contract with Customer, Liability, Noncurrent 333M USD +11.2%
Operating Lease, Liability, Noncurrent 0 USD -100%
Other Liabilities, Noncurrent 11.5M USD +18.6%
Liabilities 632M USD +29.9%
Retained Earnings (Accumulated Deficit) -1.26B USD -36%
Stockholders' Equity Attributable to Parent -254M USD -249%
Liabilities and Equity 378M USD -8.58%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -69M USD -74%
Net Cash Provided by (Used in) Financing Activities 9.9M USD -29.6%
Net Cash Provided by (Used in) Investing Activities -40K USD +81.3%
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 68.5M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -59.2M USD -129%
Interest Paid, Excluding Capitalized Interest, Operating Activities 3.74M USD +46.9%
Deferred Tax Assets, Valuation Allowance 255M USD +45.2%
Deferred Tax Assets, Gross 255M USD +45%
Operating Lease, Liability 501K USD -57.8%
Depreciation 500K USD -2.72%
Payments to Acquire Property, Plant, and Equipment 40K USD -81.3%
Lessee, Operating Lease, Liability, to be Paid 513K USD -59.4%
Property, Plant and Equipment, Gross 4.32M USD +2.98%
Operating Lease, Liability, Current 501K USD -31%
Lessee, Operating Lease, Liability, to be Paid, Year Two 513K USD -31.9%
Lessee, Operating Lease, Liability, to be Paid, Year One 513K USD -31.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 12K USD -84.4%
Deferred Tax Assets, Operating Loss Carryforwards 195M USD +62.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 40M shares 0%
Unrecognized Tax Benefits 3.45M USD +14.7%
Operating Lease, Payments 200K USD 0%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 214K USD +46.6%
Deferred Tax Assets, Net of Valuation Allowance 150K USD -56.3%
Share-based Payment Arrangement, Expense 24M USD -46.6%
Interest Expense 58.1M USD +54%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%